NEW YORK – Cambridge, Massachusetts-based Repertoire Immune Medicines on Monday announced preliminary clinical and biomarker data from an ongoing Phase I/II study of its autologous T-cell therapy, PRIME IL-15, as a treatment for patients with relapsed or refractory metastatic solid tumors.